The patent describes the extraction and standardization of stable doses of psychedelic compounds and strengthens Filament’s industry-leading IP portfolio VANCOUVER, BC, Aug. 17, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has been issued an eighth patent…
